If your BP claim has been denied by the GCCF, you need help with an existing claim, or if your business has been impacted by the BP oil spill, it is not too late to file a claim.  For a free consultation and information about about whether you have a potential claim or to receive assistance with an existing claim, please contact our team at Pendley, Baudin & Coffin, LLP by filling out the Contact Information below or by calling our toll free number:  1-800-902-7774.

WHO MAY BE ELIGIBLE TO SUBMIT A CLAIM UNDER THE SETTLEMENT?

 You may be eligible to receive monetary compensation through the economic and property damage settlement program if you have been damaged by the Deepwater Horizon oil spill in one or more of the following categories:

• Seafood Compensation
• Business Related Economic Damage  (Click here to see some listed businesses:  Tourism)
• Loss of Subsistence
• Vessel Physical Damage
• Vessels of Opportunity (VOO) Charter Payment
• Coastal Real Property Damage
• Wetlands Real Property Damage
• Real Property Sales Damage

Our team is accepting BP oil spill related business economic loss damage claims from potential clients, including but not limited to the following general categories:

•  Seafood-Related Businesses
•  Gas Stations and Convenience Stores
•  Restaurants and Bars
•  Hotels and Motels
•  Tourism-Related Businesses
•  Recreational Businesses
•  Clothing, Department and Sporting Goods Stores

DOES THE LOCATION OF MY BUSINESS AFFECT MY POTENTIAL CLAIM?

As long as your business is located in the geographic areas or “Zones” identified in the map below, you may have an eligible claim under the settlement:

WHAT IS THE VALUE OF MY POTENTIAL ECONOMIC LOSS CLAIM?

The method of calculating the amount of business loss under this settlement is unique in that the claimant defines their own compensation period.   A claimant can choose any three or more consecutive months between May and December 2010 as their compensation period (post-spill period).    A claimant then chooses a Benchmark Period of the same three or more consecutive months in prior year(s),  including the most favorable of the following time periods, against which to measure 2010 performance (pre-spill period):

• 2009
• Average of 2008 and 2009
• Average of 2007, 2008, and 2009

MULTIPLIER — An RTP multiplier will be applied to the payments for some types of Economic Damage claims, which could significantly increase the value of your potential claim.  Please contact us to discuss your multiplier that may apply to your claim.

Pendley, Baudin & Coffin has attorneys and has retained other professionals who will assist in evaluating and processing your claim.   Our team gets paid legal fees only if we are successful in recovering compensation for you.

 The credit disability insurance is routinely sold during a mortgage closing.  The credit disability insurance appears to pay the policyholder’s mortgage each month the policyholder is disabled but Household Life Insurance Company stops the mortgage payments after a twenty-four (24) month period. Household Life Insurance Company argues that it can stop the mortgage payments because the credit disability insurance policy contains a “Critical Period” which limits the number of months that Household Life Insurance Company must pay benefits for one period of disability.  However, Household Life Insurance Company does not disclose the Critical Period at the time the credit disability insurance is purchased.  Some policyholders are not told about the Critical Period in their credit disability insurance policy until after they are disabled and Household Life Insurance Company is about to improperly cut off their benefits. Even if the policyholders are provided a copy of a certificate of insurance after the mortgage closing, the certificate of insurance is ambiguous and confusing, and does not adequately disclose the Critical Period.

 Insurers have an affirmative duty to fairly deal with their insured’s in good faith. Household Life Insurance Company’s failure to properly and adequately pay its insured’s under the credit disability insurance may result in statutory penalties, including bad-faith damages and attorney’s fees.  In instances where an insured is able to prove bad faith conduct against their insurer, the penalties and damages may be substantial. Several lawsuits have been filed concerning the enforcement of the “Critical Period” in Household Life Insurance Company’s credit disability policies.

 Contact Pendley, Baudin & Coffin if Household Life Insurance Company has stopped, or threatened to stop, your credit disability insurance payments.  Pendley, Baudin & Coffin Law Firm will investigate your claim and if necessary, file a lawsuit against Household Life Insurance Company to recover the losses and damages you have suffered from the denial of your credit disability insurance benefits.

Pregnant Mother Ingests Anti-Depressant Drug; Infant Dies

PHILADELPHIA – Feb. 9, 2012 – Today, in the Philadelphia Court of Common Pleas, six attorneys from across the country filed what is believed to be the first birth defect case against EFFEXOR®, a popular and common drug used in the treatment of depression. Alleging the death of an Ohio infant was directly related to her mother’s ingestion of EFFEXOR®, the young girl’s parents are represented by Thomas Anapol and Gregory Spizer of Anapol Schwartz; Christopher Coffin and Nicholas Rockforte of Pendley, Baudin & Coffin, L.L.P.; David Landever of Weisman, Kennedy & Berris, LPA; and Tim Becker of Johnson Becker, PLLC.

The case is believed to be the first that declares a link between birth defects and use of the prescription drug, manufactured by Wyeth Pharmaceuticals and Pfizer, Inc. Also listed on the complaint is Wolters Kluwer Health/United States, Inc. as the labelers and distributors of information about the drug.

“The information that patients – especially women who are pregnant – receive about the medication that is prescribed to them is crucial,” said Thomas Anapol, a Philadelphia-based attorney heavily focused in pharmaceutical and catastrophic injury civil litigation. “This SNRI (serotonin and norepinephrine reuptake inhibitor) drug was approved by the FDA in 1993, but the parties involved neglected to disclose the birth defect risks to physicians treating women of child-bearing age.”

In Boyer & Boyer v. Wyeth Pharmaceuticals, et al., plaintiffs Glenn and Lauren Boyer were overjoyed to learn that they would be having a baby girl, who they named Adelaide. However, shortly after taking her first breath on Feb. 11, 2010, it was discovered that Adelaide suffered lethal cardiac anomalies, including severe left hypoplastic heart, a malformed aorta, no aortic value, a malformed mitral valve and other related conditions. The Boyers allege that the anomalies were caused by Mrs. Boyer’s use of EFFEXOR®.

The filed complaint contains 16 individual counts against the three defendants. In addition to failure to warn and negligence claims, the suit alleges that fraud and misrepresentation led to Adelaide’s death.

“It is likely that the defendants had evidence to the contrary of what was disseminated for public information,” according to registered nurse and attorney Christopher Coffin of New Orleans, La., who specializes in pharmaceutical litigation throughout the country. “To minimize and understate the risks was to place Adelaide and her family in an experiment they would never have consented to.”

For more information on EFFEXOR® and other prescription drug litigation contact 1-888-725-2477.

 The U.S. Food and Drug Administration approved Infuse for only anterior approach lumbar fusion surgery.  Many patients have received Infuse in off-label uses in either the lumbar or cervical spine.  The FDA has not authorized Infuse in either lateral or posterior approach lumbar fusion surgeries or for use in the cervical spine.

 The patient must be informed of off-label or experimental use of a drug or medical devise by a physician prior to surgery and full disclosure of the risk.  Many patients who received off-label use of Infuse in their spine were not informed.  Specific side effects reported from the off-label use of Infuse:

• Ectopic bone growth or uncontrolled bone growth in the spinal canal
• Ongoing or chronic radiating pain in the legs or arms called radiculopathy or radiculitis
• Sterility, retrograde ejaculation, or other urogenital injuries in male patients
• In cervical spine surgeries: acute neck swelling several days after surgery resulting in death or permanent injury
• Nerve injuries causing chronic pain

If you are a family member were seriously injured after receiving Infuse, Please fill out the Contact Us section below for a confidential case evaluation.

The Type-2 diabetes drug Actos (also marketed as Duetact, Actoplus and Actoplus Met), which was manufactured, developed and distributed by Takeda Pharmaceuticals, has recently been linked to an increased risk of bladder cancer.

In June of 2011, Actos was removed from the markets in France and Germany after studies revealed a potential increased risk of bladder cancer associated with Actos.  Shortly thereafter, also in June of 2011, the U.S. Food and Drug Administration (FDA) issued a warning that Actos may be linked to an increased risk of bladder cancer, especially in those who have taken Actos for more than a year.  Consequently, the FDA required the maker of Actos to include information about the risk of bladder cancer associated with Actos on its warning label.

The attorneys at Pendley, Baudin & Coffin are here to help you with your Actos lawsuit.  Our firm has more than 20 years in pharmaceutical litigation and has represented thousands of consumers who have been injured by pharmaceutical drugs such as Actos.  We have helped others triumph over major pharmaceutical companies, and we can help you find justice as well. 

If you or a loved one is a diabetic who has been diagnosed with bladder cancer while taking Actos, you have the legal right to seek compensation for your losses and suffering through an Actos lawsuit.  For a free consultation to speak with a qualified and experienced lawyer, who will listen to your story, answer your Actos related questions, discuss your options, and offer the help you need to obtain the compensation you deserve, we invite you to phone us at the numbers listed on our website or to fill out the contact us listed below. 

On Thursday, U.S. District Judge Eldon Fallon in New Orleans announced the settlement.  The settlement calls for Knauf to create an uncapped fund to pay for repairs for an estimated 4,500 homes in Florida, Louisiana, Mississippi and Alabama.  Judge Fallon must sign-off on the settlement before any money is distributed.  The estimated value of the settlement is between $800 million and $1 billion.